Behandlingsniveau og behandlingsstop ved benign lungesygdom

Anita Rath Sørensen; Elisabeth Bendstrup; Anders Løkke; Ingrid Louise Titlestad; Jens Ulrik Jensen; Laura Thomsen; Nassim Roberts; Pia Gjørup; Saher Shaker; Svend Gundestrup; Torgny Wilcke; Ulla Møller Weinreich; Kristoffer Marsaa

Behandlingsniveau og behandlingsstop ved benign lungesygdom

Anita Rath Sørensen, Elisabeth Bendstrup, Anders Løkke, Ingrid Louise Titlestad, Jens Ulrik Jensen, Laura Thomsen, Nassim Roberts, Pia Gjørup, Saher Shaker, Svend Gundestrup, Torgny Wilcke, Ulla Møller Weinreich, Kristoffer Marsaa

Abstract

The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

Bidragets oversatte titel	Treatment limitations or discontinuation in patients with benign pulmonary diseases
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	180
Udgave nummer	39
ISSN	0041-5782
Status	Udgivet - 24 sep. 2018

Citationsformater

@article{58899442281a4c1cb1ab7dc6ef4a8f2a,

title = "Behandlingsniveau og behandlingsstop ved benign lungesygdom",

abstract = "The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.",

author = "S{\o}rensen, {Anita Rath} and Elisabeth Bendstrup and Anders L{\o}kke and Titlestad, {Ingrid Louise} and Jensen, {Jens Ulrik} and Laura Thomsen and Nassim Roberts and Pia Gj{\o}rup and Saher Shaker and Svend Gundestrup and Torgny Wilcke and Weinreich, {Ulla M{\o}ller} and Kristoffer Marsaa",

year = "2018",

month = sep,

day = "24",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "39",

}

TY - JOUR

T1 - Behandlingsniveau og behandlingsstop ved benign lungesygdom

AU - Sørensen, Anita Rath

AU - Bendstrup, Elisabeth

AU - Løkke, Anders

AU - Titlestad, Ingrid Louise

AU - Jensen, Jens Ulrik

AU - Thomsen, Laura

AU - Roberts, Nassim

AU - Gjørup, Pia

AU - Shaker, Saher

AU - Gundestrup, Svend

AU - Wilcke, Torgny

AU - Weinreich, Ulla Møller

AU - Marsaa, Kristoffer

PY - 2018/9/24

Y1 - 2018/9/24

N2 - The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

AB - The decision to limit or discontinue treatment is a difficult issue, which all physicians will face. Timely communication with information on treatment possibilities and limitations, respectful listening to patients' and informal caregivers' wishes and early palliation is recommended in a stable phase. In some situations, it is better to stop life-prolonging treatment and optimise quality of life in patients with benign pulmonary diseases. Decision on treatment limitations or discontinuation is best taken at a conference and should be based on the patient's wishes, the disease stage and progression and potential reversible components.

M3 - Tidsskriftartikel

C2 - 30274574

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 39

ER -

Behandlingsniveau og behandlingsstop ved benign lungesygdom

Abstract

Fingeraftryk

Citationsformater